# US 2024/0216498 A1 · Large-scale flaviviral vaccine production and manufacture

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0216498 A1
- Document ID: US20240216498A1
- Status: Published application
- Kind: A1
- Application number: 18/523,331
- Filed: 2023-11-29
- Published: 2024-07-04
- Earliest claimed: 2022-01-25
- Assignees: Takeda Vaccines, Inc.
- Applicants: Takeda Vaccines, Inc.
- Inventors: Joseph David Santangelo; Jill A. Livengood; Yock Ann Lee; Weiwen Luo
- Web page: https://patentgrep.com/patent/US20240216498A1

## CPC

- A61K 39/12: Viral antigens
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5254: {avirulent or attenuated}
- C12N 2770/24121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24152: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2770/24162: by genetic engineering
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides methods for large-scale flaviviral vaccine production and manufacture. The methods provided herein are specifically contemplated for large-scale production and manufacture of live, attenuated flaviviral vaccines such as live, attenuated, dengue virus vaccines. Further, the methods provided herein pertain to formulation of live, attenuated, monovalent, divalent, trivalent, or tetravalent viral vaccine products.

## Claims

### Claim 1

A method of large-scale flaviviral vaccine production and manufacture comprising
a harvesting step to obtain a harvest,
obtaining a bulk drug substance from the harvest,
processing the bulk drug substance comprising a step of filtering the bulk drug substance followed by a step of freezing the bulk drug substance to obtain a frozen bulk drug substance.

### Claim 2 (depends on 1)

The method of claim 1, wherein the harvest does not undergo a freezing step until the step of processing the bulk drug substance.

### Claim 3 (depends on 1)

The method of claim 1, wherein processing the bulk drug substance does not involve a freezing step before the filtration step.

### Claim 4 (depends on 1)

The method of claim 1, wherein the harvest does not undergo a freezing step until the step of processing the bulk drug substance and wherein processing the bulk drug substance does not involve a freezing step before the filtration step.

### Claim 5 (depends on 1)

The method of claim 1, wherein the step of filtering comprises agitating the bulk drug substance.

### Claim 6 (depends on 1)

The method of claim 1, wherein the step of filtering comprises agitating the bulk drug substance for at least 1 minute such as 5 minutes.

### Claim 7 (depends on 1)

The method of claim 1, wherein the step of freezing comprises freezing the bulk drug substance at a temperature of less than −65° C.

### Claim 8 (depends on 1)

The method claim 1, wherein the weight of the frozen bulk drug substance is at least 100 g.

### Claim 9 (depends on 1)

The method of claim 1, comprising
a harvesting step to obtain a harvest,
ultrafiltration optionally tangential flow filtration to obtain a drug substance, and
at least one flushing step of the ultrafiltration membrane with a flushing buffer to obtain a composition comprising a buffer flush and drug substance, which is the bulk drug substance.

### Claim 10 (depends on 1)

The method of claim 1, comprising
a harvesting step to obtain a harvest,
processing the harvest to obtain a processed harvest,
ultrafiltration optionally tangential flow filtration to obtain a drug substance, and
at least one flushing step of the ultrafiltration membrane with a flushing buffer to obtain a composition comprising a buffer flush and drug substance, which is the bulk drug substance.

### Claim 11 (depends on 1)

The method of claim 1, comprising
a harvesting step to obtain a harvest,
processing the harvest to obtain a processed harvest,
purification comprising at least one chromatography step such as an anion exchange chromatography to obtain a purified harvest,
ultrafiltration optionally tangential flow filtration to obtain a drug substance, and
at least one flushing step of the ultrafiltration membrane with a flushing buffer to obtain a composition comprising a buffer flush and drug substance, which is the bulk drug substance.

### Claim 12 (depends on 1)

The method of claim 1, comprising
a harvesting step to obtain a harvest,
processing the harvest comprising clarification and stabilization of the harvest to obtain a clarified and stabilized harvest,
purification of the clarified and stabilized harvest comprising at least one chromatography step such as an anion exchange chromatography to obtain a purified harvest,
ultrafiltration optionally tangential flow filtration on the purified harvest to obtain a drug substance, and
at least one flushing step of the ultrafiltration membrane with a flushing buffer to obtain a composition comprising a buffer flush and drug substance, which is the bulk drug substance.

### Claim 13 (depends on 1)

The method of claim 1, comprising the following sequential steps preceding the harvesting step:
providing cells in growth media,
infecting cells with media comprising a flavivirus.

### Claim 14 (depends on 13)

The method of claim 13, wherein infecting the cells with media comprising a flavivirus comprises infecting the cells at an MOI of 0.1 to less than 0.008.

### Claim 15 (depends on 1)

The method of am claim 1, wherein the method provides for high viral titres.

### Claim 16 (depends on 1)

The method of claim 1, wherein the method provides for higher viral titres as compared to a method differing only in that processing the bulk drug substance comprises freezing the bulk drug substance before filtering the bulk drug substance.

### Claim 17

A method of large-scale flaviviral vaccine production and manufacture comprising
at least two harvesting steps to obtain at least two harvests,
obtaining at least two bulk drug substances from the at least two harvests,
processing the at least two bulk drug substances comprising a step of filtering each of the at least two bulk drug substances followed by a step of freezing each of the at least two bulk drug substances to obtain at least two frozen bulk drug substances.

### Claim 18 (depends on 17)

The method of claim 17, wherein the at least two frozen bulk drug substances are thawed and optionally pooled.

### Claim 19 (depends on 17)

The method of claim 17, wherein each of the at least two harvests do not undergo a freezing step until the step of processing the at least two bulk drug substances.

### Claim 20 (depends on 17)

The method of claim 17, wherein processing the at least two bulk drug substances does not involve a freezing step before the filtration step.

### Claim 21 (depends on 17)

The method of claim 17, wherein each of the at least two harvests do not undergo a freezing step until the step of processing the at least two bulk drug substances and wherein processing the at least two bulk drug substances does not involve a freezing step before the filtration step.

### Claim at position 22

-25. (canceled)

### Claim 26 (depends on 17)

The method of claim 17, comprising
at least two harvesting steps to obtain at least two harvests, and
performing the following steps for each of the at least two harvests
ultrafiltration optionally tangential flow filtration to obtain a drug substance, and
at least one flushing step of the ultrafiltration membrane with a flushing buffer to obtain a composition comprising a buffer flush and drug substance, which is the bulk drug substance,
to obtain at least two drug substances and at least two bulk drug substances.

### Claim 27 (depends on 17)

The method of claim 17, comprising
at least two harvesting steps to obtain at least two harvests, and
performing the following steps for each of the at least two harvests
processing the harvest to obtain a processed harvest,
ultrafiltration optionally tangential flow filtration to obtain a drug substance, and
at least one flushing step of the ultrafiltration membrane with a flushing buffer to obtain a composition comprising a buffer flush and drug substance, which is the bulk drug substance,
to obtain at least two processed harvests, at least two drug substances and at least two bulk drug substances.

### Claim 28 (depends on 17)

The method of claim 17, comprising
at least two harvesting steps to obtain at least two harvests, and
performing the following steps for each of the at least two harvests
processing the harvest to obtain a processed harvest,
purification comprising at least one chromatography step such as an anion exchange chromatography to obtain a purified,
ultrafiltration optionally tangential flow filtration to obtain a drug substance, and
at least one flushing step of the ultrafiltration membrane with a flushing buffer to obtain a composition comprising a buffer flush and drug substance, which is the bulk drug substance,
to obtain at least two processed harvests, at least two purified harvests, at least two drug substances and at least two bulk drug substances.

### Claim 29 (depends on 17)

The method of claim 17, comprising
at least two harvesting steps to obtain at least two harvests, and
performing the following steps for each of the at least two harvests
processing the harvest comprising clarification and stabilization of the harvest to obtain a clarified and stabilized harvest,
purification of the clarified and stabilized harvest comprising at least one chromatography step such as an anion exchange chromatography to obtain a purified harvest,
ultrafiltration optionally tangential flow filtration to obtain a drug substance, and
at least one flushing step of the ultrafiltration membrane with a flushing buffer to obtain a composition comprising a buffer flush and drug substance, which is the bulk drug substance,
to obtain at least two clarified and stabilized harvests, at least two purified harvests, at least two drug substances and at least two bulk drug substances.

### Claim 30 (depends on 17)

The method of claim 17, comprising the following steps before the harvesting step:
providing cells in growth media,
infecting cells with media comprising flavivirus.

### Claim 31 (depends on 30)

The method of claim 30, wherein infecting the cells with media comprising a flavivirus comprises infecting the cells at an MOI of 0.1 to less than 0.008.

### Claim 32 (depends on 17)

The method of claim 17, wherein the method provides for high viral titres.

### Claim 33 (depends on 17)

The method of claim 17, wherein the method provides for higher viral titres as compared to a method differing only in that processing the bulk drug substances comprises freezing the bulk drug substances followed by filtering the bulk drug substances.

### Claim at position 31

-43. (canceled)

### Claim 44 (depends on 17)

The method of claim 17, wherein the viral vaccine is divalent, trivalent or tetravalent, preferably wherein the viral vaccine is a tetravalent dengue vaccine TAK-003.

### Claim 45 (depends on 17)

The method of claim 17, wherein large-scale comprises production cultures of surface area 35,000 cm2 or more, 50,000 cm2 or more, 100,000 cm2 or more.

### Claim 46 (depends on 17)

The method of claim 17, wherein the flavivirus is a live, attenuated dengue virus selected from a group consisting of dengue serotype 1 (DENV-1) such as a dengue 2/1 chimera, dengue serotype 2 (DENV-2), dengue serotype 3 (DENV-3) such as a dengue 2/3 chimera and dengue serotype 4 (DENV-4) such as a dengue 2/4 chimera.

### Claim 47 (depends on 17)

The method of claim 17, wherein the flavivirus is a live, attenuated dengue virus selected from a group consisting of TDV-1 represented by SEQ ID NO: 1 and/or 2, TDV-2 represented by SEQ ID NO: 3 and/or 4, TDV-3 represented by SEQ ID NO: 5 and/or 6, and TDV-4 represented by SEQ ID NO: 7 and/or 8.

### Claim 48 (depends on 1)

The method of claim 1, wherein the viral vaccine is divalent, trivalent or tetravalent, preferably wherein the viral vaccine is a tetravalent dengue vaccine TAK-003.

### Claim 49 (depends on 1)

The method of claim 1, wherein large-scale comprises production cultures of surface area 35,000 cm2 or more, 50,000 cm2 or more, 100,000 cm2 or more.

### Claim 50 (depends on 1)

The method of claim 1, wherein the flavivirus is a live, attenuated dengue virus selected from a group consisting of dengue serotype 1 (DENV-1) such as a dengue 2/1 chimera, dengue serotype 2 (DENV-2), dengue serotype 3 (DENV-3) such as a dengue 2/3 chimera and dengue serotype 4 (DENV-4) such as a dengue 2/4 chimera.

### Claim 51 (depends on 1)

The method of claim 1, wherein the flavivirus is a live, attenuated dengue virus selected from a group consisting of TDV-1 represented by SEQ ID NO: 1 and/or 2, TDV-2 represented by SEQ ID NO: 3 and/or 4, TDV-3 represented by SEQ ID NO: 5 and/or 6, and TDV-4 represented by SEQ ID NO: 7 and/or 8.
